Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Zighereda Ogbah
Observed name:
Z. Ogbah
Institution:
Vall d'Hebron Institute of Oncology
Observed institutions:
Instituto de Salud Carlos III,
Centre for Biomedical Network Research on Rare Diseases,
Hospital Clínic de Barcelona,
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer,
Vall d'Hebron Institute of Oncology,
Universitat de Barcelona
show all 6
ORCID:
0000-0001-9221-0029
Observed ORCID:
0000-0001-9221-0029
OpenAlex ID:
A5066100303
Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study
2012
·
John R. Davies
, Juliette Randerson‐Moor
, et al.
·
Pigment Cell & Melanoma Research
·
76
PDF
Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom
2014
·
Mark Harland
, Anne E Cust
, et al.
·
Hereditary Cancer in Clinical Practice
·
70
Genetic alterations in RAS ‐regulated pathway in acral lentiginous melanoma
2012
·
Joan A. Puig‐Butillé
, Celia Badenas
, et al.
·
Experimental Dermatology
·
54
PDF
Serum 25-hydroxyvitamin D3 levels and vitamin D receptor variants in melanoma patients from the Mediterranean area of Barcelona
2013
·
Zighereda Ogbah
, Laura Visa
, et al.
·
BMC Medical Genetics
·
31
PDF
Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials
2020
·
Rodrigo Dienstmann
, Elena Garralda
, et al.
·
JCO Precision Oncology
·
26
PDF
Inherited variation in the PARP1 gene and survival from melanoma
2014
·
John R. Davies
, Rosalyn Jewell
, et al.
·
International Journal of Cancer
·
26
PDF
High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
2021
·
Mònica Sánchez-Guixé
, Cinta Hierro
, et al.
·
Clinical Cancer Research
·
25
Impact of Sunscreens on Preventing UVR-Induced Effects in Nevi: In Vivo Study Comparing Protection Using a Physical Barrier vs Sunscreen
2013
·
Cristina Carrera
, Joan A. Puig-Butillè
, et al.
·
JAMA Dermatology
·
19
Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial
2019
·
Jaume Capdevila
, Ignacio Matos
, et al.
·
Molecular Cancer Therapeutics
·
13
Evaluation of PAX 3 genetic variants and nevus number
2013
·
Zighereda Ogbah
, Celia Badenas
, et al.
·
Pigment Cell & Melanoma Research
·
12
Genetic variation at KIT locus may predispose to melanoma
2012
·
Agnes Bourillon
, Hui‐Han Hu
, et al.
·
Pigment Cell & Melanoma Research
·
11
Molecular characterization of human cutaneous melanoma-derived cell lines.
2012
·
Zighereda Ogbah
, Joan Anton Puig-Butille
, et al.
·
PubMed
·
11
MYC Copy Number Detection in Clinical Samples Using a Digital DNA-Hybridization and Detection Method
2021
·
Zighereda Ogbah
, Francesco Mattia Mancuso
, et al.
·
Methods in molecular biology
·
3
RNAseq analysis of the sorafenib phase III DECISION trial in differentiated thyroid cancer (DTC): Correlation with clinical outcome.
2017
·
Jaume Capdevila
, Ignacio Matos Garcia
, et al.
·
Journal of Clinical Oncology
·
2
Prognostic impact of RNA expression profile (EP) in the phase III DECISION trial for patients with advanced radioactive-iodine refractory differentiated thyroid cancer (DTC)
2017
·
I. Matos
, F. Mancuso
, et al.
·
Annals of Oncology
·
1
Analysis of RSPO gene expression in solid tumors.
2016
·
Ana Vivancos
, Hector G. Palmer
, et al.
·
Journal of Clinical Oncology
·
1
Mutation of the tumour suppressor p33ING1b is rare in cutaneous melanoma
2006
·
J. Puig Butille
, M. Stark
, et al.
·
Melanoma Research
·
1
Data from Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial
2023
·
Jaume Capdevila
, Ignacio Matos
, et al.
Supplementary Data from Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial
2023
·
Jaume Capdevila
, Ignacio Matos
, et al.
PDF
Data from Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial
2023
·
Jaume Capdevila
, Ignacio Matos
, et al.
Supplementary Table S2 from High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
2023
·
Mònica Sánchez-Guixé
, Cinta Hierro
, et al.
Supplementary Figure Legends from High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
2023
·
Mònica Sánchez-Guixé
, Cinta Hierro
, et al.
Figure S5 from High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
2023
·
Mònica Sánchez-Guixé
, Cinta Hierro
, et al.
PDF
Supplementary Table S1 from High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
2023
·
Mònica Sánchez-Guixé
, Cinta Hierro
, et al.
Figure S4 from High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
2023
·
Mònica Sánchez-Guixé
, Cinta Hierro
, et al.
Show more works
View as search
Works count:
39
Citation count:
382
H-index:
11
I10-index:
12
Year
Topic
Type